Author(s):
Prachi S. Pawar, Laxmikant M. Purane, Sanika S. Chavan, Prathamesh P. Kamble, Mansi G. Gujare
Email(s):
Prachipawar4009@gmail.com
DOI:
10.52711/2231-5713.2026.00045 
Address:
Prachi S. Pawar, Laxmikant M. Purane, Sanika S. Chavan, Prathamesh P. Kamble, Mansi G. Gujare
Department of Pharmacology, Yashoda Technical Campus, Satara,
Dr. Babasaheb Ambedkar Technological University, Lonere 402103, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
DPN is a severe condition that manifests if a person has had diabetes for a long time. Neuropathy, excess free oxygen, inflammation, and disrupted neurotrophic systems are signs of damage to small blood vessels and the body's abnormal metabolic processes. The majority of the symptom-based medications that are currently on the market are less effective and have more adverse effects. As we travel as Positive outcomes have been obtained with plants and active principles produced from them. Any plant that contains a variety of phytoconstituents that operate on various bodily regions and receptors. This article discusses a number of plants that have historically been used to treat neuropathy and diabetes. The molecular mechanisms of action of a variety of phytoconstituents include flavonoids, terpenoids, alkaloids, saponins, and phenolic compounds. Their effects on several receptors linked to diabetes and neuropathy, including the insulin receptor, GLP-1 and GIP receptors, PPAR-?, KATP channels, SGLT2, and inflammatory receptors for neuropathy including TLR4 and TNF-a, are also reviewed. Research has shown that substances like quercetin, berberine, curcumin, ginsenosides, and mangifera improve the effectiveness of insulin, lower free oxygen, inhibit the harmful enzyme aldose reductase, reduce inflammation, improve microvessel blood flow, and encourage nerve regeneration. More than 45 plants and their bioactive compounds have been discussed in this research, offering sufficient scientific support for the creation of novel drugs. All things considered, plant compounds hold great potential for both neuroprotection and blood sugar regulation in DPN. This calls for additional research on humans, animals, and new.
Cite this article:
Prachi S. Pawar, Laxmikant M. Purane, Sanika S. Chavan, Prathamesh P. Kamble, Mansi G. Gujare. A Thorough Review of Plant-Based Treatments for Diabetic Peripheral Neuropathy: Phytoconstituent-Mediated Modulation of Diabetic and Neuropathic Receptors. Asian Journal of Pharmacy and Technology. 2026; 16(3):322-0. doi: 10.52711/2231-5713.2026.00045
Cite(Electronic):
Prachi S. Pawar, Laxmikant M. Purane, Sanika S. Chavan, Prathamesh P. Kamble, Mansi G. Gujare. A Thorough Review of Plant-Based Treatments for Diabetic Peripheral Neuropathy: Phytoconstituent-Mediated Modulation of Diabetic and Neuropathic Receptors. Asian Journal of Pharmacy and Technology. 2026; 16(3):322-0. doi: 10.52711/2231-5713.2026.00045 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-3-15
REFERENCE:
1. Manu Bala RKJKMKSS. Assessment of Quality of Life among Diabetic Patients Visiting Medical Out Patient Department at Selected Health Care Facilities at Punjab. A and V publication.
2. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: A systematic review and meta-analysis. PLoS ONE; 4. Epub ahead of print 7 January 2009. DOI: 10.1371/journal.pone.0004144.
3. Kumari Anjali Jain. A Mechanistic Approach to Determination of Anti-diabetic activity of Calystegia sepium R.Br. Flowering plants in normal and Streptozotocin induced rats. A and V Publication 2014; 55–70.
4. Warncke K, Weiss A, Achenbach P, et al. Elevations in blood glucose before and after the appearance of islet autoantibodies in children. Journal of Clinical Investigation; 132. Epub ahead of print 17 October 2022. DOI: 10.1172/JCI162123.
5. Harikrishnan.V SreejithMElthoseMJAM. Gelucire: An Optional Innovative Tool for both Sustained and Fast Release of Drugs in Treating Diabetes Mellitus Type II Disease. A and V Publication 2017; 33–37.
6. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. International Journal of Molecular Sciences. 2020; 21: 1–34.
7. Pattabiraman K. MP. Antidiabetic and Antioxidant Activity of Morinda tinctoria roxb Fruits Extract in Streptozotocin-Induced Diabetic Rats. A and V Publication .2011; 34–39.
8. Marshall A, Alam U, Themistocleous A, et al. Novel and Emerging Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy. Clinical Therapeutics 2021; 43: 1441–1456.
9. Liu H, Liu Q, Chen M, et al. Construction and validation of a nomogram model for predicting diabetic peripheral neuropathy. Front Endocrinol (Lausanne); 15. Epub ahead of print 2024. DOI: 10.3389/fendo.2024.1419115.
10. Józefowicz RF. Peripheral Neuropathy.
11. Lamotte G, Sandroni P. Updates on the Diagnosis and Treatment of Peripheral Autonomic Neuropathies. Current Neurology and Neuroscience Reports 2022; 22: 823–837.
12. Bell DSH. Diabetic Mononeuropathies and Diabetic Amyotrophy. Diabetes Therapy 2022; 13: 1715–1722.
13. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American diabetes association. Diabetes Care 2017; 40: 136–154.
14. Salehi B, Ata A, Kumar NVA, et al. Antidiabetic potential of medicinal plants and their active components. Biomolecules; 9. Epub ahead of print 1 October 2019. DOI: 10.3390/biom9100551.
15. Kooti W, Farokhipour M, Asadzadeh Z, et al. The role of medicinal plants in the treatment of diabetes: a systematic review. Electron Physician 2016; 8: 1832–1842.
16. Kooti W, Farokhipour M, Asadzadeh Z, et al. The role of medicinal plants in the treatment of diabetes: a systematic review. Electron Physician 2016; 8: 1832–1842.
17. Nasri H, Shirzad H, Baradaran A, et al. Antioxidant plants and diabetes mellitus. 2015.
18. Amiza GYSS. Comprehensive Review on Phytopharmacological Potential of Gymnema sylvestre. A and V Publication.
19. Simmons KM, Gottlieb PA, Michels AW. Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes. Current Diabetes Reports; 16. Epub ahead of print 1 October 2016. DOI: 10.1007/s11892-016-0793-8.
20. Cui D, Feng X, Lei S, et al. Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes. Chinese Medical Journal 2024; 137: 791–805.
21. Suresh Kumar Sutrakar DSB. Biochemical Parameters Variations in Type–II Diabetes Mellitus: Special Reference in Rewa Region. A and V P ublication 2014; 877–881.
22. Zhu J, Hu Z, Luo Y, et al. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Front Endocrinol (Lausanne); 14. Epub ahead of print 9 January 2024. DOI: 10.3389/fendo.2023.1265372.
23. Parvathy Pavithran RMJSJSVSSSTMSMSJAAK. Effect of Video Assisted Teaching on Practice of Self Administration of Insulin among Diabetic patients. A and V Pub International Journal of Nursing and Medical Research.
24. Schreiber AK. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes 2015; 6: 432.
25. Pushpendra Kumar TXMVChoudhary. An experimental study to assess the effectiveness of structured teaching programme on knowledge regarding the management of diabetes mellitus among G.N.M. A AND V PUBLICATION 2014; 329–331.
26. Rosenzweig T, Sampson SR. Activation of insulin signaling by botanical products. International Journal of Molecular Sciences; 22. Epub ahead of print 2 April 2021. DOI: 10.3390/ijms22084193.
27. Rosenzweig T, Sampson SR. Activation of insulin signaling by botanical products. International Journal of Molecular Sciences; 22. Epub ahead of print 2 April 2021. DOI: 10.3390/ijms22084193.
28. Md Sayem AS, Arya A, Karimian H, et al. Action of phytochemicals on insulin signaling pathways accelerating glucose transporter (GLUT4) protein translocation. Molecules; 23. Epub ahead of print 2018. DOI: 10.3390/molecules23020258.
29. Williamson G, Sheedy K. Effects of polyphenols on insulin resistance. Nutrients 2020; 12: 1–19.
30. Virendra Singh Choudhary GChaudhary. A Descriptive Study to Assess the Knowledge Regarding Diabetes Mellitus, Its Risk Factors and Complication among the Rural Community Sadiq, Faridkot (Punjab). Asian J. Nur. Edu. and Research 5(2). A and v publication.
31. Liu C, Wu L, Fu L, et al. Mangiferin prevents glucolipotoxicity-induced pancreatic beta-cell injury through modulation of autophagy via AMPK-mTOR signaling pathway. Arch Physiol Biochem 2025; 131: 71–80.
32. Abiola JO, Oluyemi AA, Idowu OT, et al. Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus. Pharmaceuticals; 17. Epub ahead of print 1 June 2024. DOI: 10.3390/ph17060736.
33. Abiola JO, Oluyemi AA, Idowu OT, et al. Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus. Pharmaceuticals; 17. Epub ahead of print 1 June 2024. DOI: 10.3390/ph17060736.
34. Kolhe RC, Chaudhari PS, Khaire MP, et al. Natural Bioactives Targeting the GLP-1 Pathway: A Promising Approach for Diabetes Management. Pharmacogn Rev 2025; 19: 1–14.
35. Abiola JO, Oluyemi AA, Idowu OT, et al. Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus. Pharmaceuticals; 17. Epub ahead of print 1 June 2024. DOI: 10.3390/ph17060736.
36. Kim KS, Jang HJ. Medicinal plants qua glucagon-like peptide-1 secretagogue via intestinal nutrient sensors. Evidence-based Complementary and Alternative Medicine; 2015. Epub ahead of print 2015. DOI: 10.1155/2015/171742.
37. Oh YS. Plant-derived compounds targeting pancreatic beta cells for the treatment of diabetes. Evidence-based Complementary and Alternative Medicine; 2015. Epub ahead of print 2015. DOI: 10.1155/2015/629863.
38. Abiola JO, Oluyemi AA, Idowu OT, et al. Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus. Pharmaceuticals; 17. Epub ahead of print 1 June 2024. DOI: 10.3390/ph17060736.
39. Kolhe RC, Chaudhari PS, Khaire MP, et al. Natural Bioactives Targeting the GLP-1 Pathway: A Promising Approach for Diabetes Management. Pharmacogn Rev 2025; 19: 1–14.
40. Ahmadian M, Suh JM, Hah N, et al. Pparγ signaling and metabolism: The good, the bad and the future. Nat Med 2013; 19: 557–566.
41. Ashcroft FM. KATP Channels and the Metabolic Regulation of Insulin Secretion in Health and Disease: The 2022 Banting Medal for Scientific Achievement Award Lecture. Diabetes 2023; 72: 693–702.
42. Ashcroft FM. KATP Channels and the Metabolic Regulation of Insulin Secretion in Health and Disease: The 2022 Banting Medal for Scientific Achievement Award Lecture. Diabetes 2023; 72: 693–702.
43. Pabbidi MR, Premkumar LS. Role of Transient Receptor Potential Channels Trpv1 and Trpm8 in Diabetic Peripheral Neuropathy HHS Public Access. 2017.
44. Pabbidi MR, Premkumar LS. Role of Transient Receptor Potential Channels Trpv1 and Trpm8 in Diabetic Peripheral Neuropathy HHS Public Access. 2017.
45. Obata K, Katsura H, Mizushima T, et al. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. Journal of Clinical Investigation 2005; 115: 2393–2401.
46. Bigsby S, Neapetung J, Campanucci VA. Voltage-gated sodium channels in diabetic sensory neuropathy: Function, modulation, and therapeutic potential. Frontiers in Cellular Neuroscience; 16. Epub ahead of print 17 November 2022. DOI: 10.3389/fncel.2022.994585.
47. Bigsby S, Neapetung J, Campanucci VA. Voltage-gated sodium channels in diabetic sensory neuropathy: Function, modulation, and therapeutic potential. Frontiers in Cellular Neuroscience; 16. Epub ahead of print 17 November 2022. DOI: 10.3389/fncel.2022.994585.
48. Du X, Gamper N. Send Orders for Reprints to reprints@benthamscience.net Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential. 2013.
49. Schreiber AK. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes 2015; 6: 432.
50. Schreiber AK. Diabetic neuropathic pain: Physiopathology and treatment. World J Diabetes 2015; 6: 432.
51. Zhou H, Rao Z, Zhang Z, et al. Function of the GABAergic System in Diabetic Encephalopathy. Cellular and Molecular Neurobiology 2023; 43: 605–619.
52. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2011; 115: 1363–1381.
53. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2011; 115: 1363–1381.
54. M Lima L. Novel Partial Agonist of PPAR-Gamma for Treatment of Diabetic Neuropathy in Rats. J Diabetes Metab; 05. Epub ahead of print 2014. DOI: 10.4172/2155-6156.1000392.
55. Williamson G, Sheedy K. Effects of polyphenols on insulin resistance. Nutrients 2020; 12: 1–19.
56. Williamson G, Sheedy K. Effects of polyphenols on insulin resistance. Nutrients 2020; 12: 1–19.
57. Hazaratali Panari VegunaraniM. Study on Complications of Diabetes Mellitus among the Diabetic Patients. Asian J. Nur. Edu. and Research. A nad V Publication.
58. Song W, Li Y, Jia Y, et al. Quercetin Alleviates Diabetic Peripheral Neuropathy by Regulating Axon Guidance Factors and Inhibiting the Rho/ROCK Pathway in vivo and in vitro. Diabetes, Metabolic Syndrome and Obesity 2024; 17: 4339–4354.
59. Zhang Q, Song W, Zhao B, et al. Quercetin Attenuates Diabetic Peripheral Neuropathy by Correcting Mitochondrial Abnormality via Activation of AMPK/PGC-1α Pathway in vivo and in vitro. Front Neurosci; 15. Epub ahead of print 3 March 2021. DOI: 10.3389/fnins.2021.636172.
60. Solnier J, Zhang Y, Roh K, et al. A Pharmacokinetic Study of Different Quercetin Formulations in Healthy Participants: A Diet‐Controlled, Crossover, Single‐ and Multiple‐Dose Pilot Study. Evidence-Based Complementary and Alternative Medicine; 2023. Epub ahead of print January 2023. DOI: 10.1155/2023/9727539.
61. Shom Prakash Kushwaha SKRPKAKT. Coupling Antioxidant and Antidiabetic assets of 2, 4-Thiazolidinedione Derivatives. . A and V Publication 2011; 71–73.
62. Song W, Li Y, Jia Y, et al. Quercetin Alleviates Diabetic Peripheral Neuropathy by Regulating Axon Guidance Factors and Inhibiting the Rho/ROCK Pathway in vivo and in vitro. Diabetes, Metabolic Syndrome and Obesity 2024; 17: 4339–4354.
63. Zhu C, Liu N, Tian M, et al. Effects of alkaloids on peripheral neuropathic pain: A review. Chinese Medicine (United Kingdom); 15. Epub ahead of print 2 October 2020. DOI: 10.1186/s13020-020-00387-x.
64. Zhu C, Liu N, Tian M, et al. Effects of alkaloids on peripheral neuropathic pain: A review. Chinese Medicine (United Kingdom); 15. Epub ahead of print 2 October 2020. DOI: 10.1186/s13020-020-00387-x.
65. Zhu C, Liu N, Tian M, et al. Effects of alkaloids on peripheral neuropathic pain: A review. Chinese Medicine (United Kingdom); 15. Epub ahead of print 2 October 2020. DOI: 10.1186/s13020-020-00387-x.
66. Lou J-S, Dimitrova DM, Murchison C, et al. Centella asiatica triterpenes for diabetic neuropathy: a randomized, double-blind, placebo-controlled, pilot clinical study. Esper Dermatol; 20. Epub ahead of print 1 July 2021. DOI: 10.23736/s1128-9155.18.00455-7.
67. Nazaruk J, Borzym-Kluczyk M. The role of triterpenes in the management of diabetes mellitus and its complications. Phytochemistry Reviews 2015; 14: 675–690.
68. Zhou JY, Zhou SW. Protection of trigonelline on experimental diabetic peripheral neuropathy. Evidence-based Complementary and Alternative Medicine; 2012. Epub ahead of print 2012. DOI: 10.1155/2012/164219.